Drugs Made In America Acquisition Corp Rights
DMAAR
32 hedge funds and large institutions have $3.07M invested in Drugs Made In America Acquisition Corp Rights in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
1% more capital inflows, than outflows
Capital inflows: $76K | Capital outflows: $75.3K
0% more funds holding
Funds holding: 32 → 32 (0)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$23.2K |
| 2 |
DLD Asset Management
New York
|
+$19.7K |
| 3 |
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$19.4K |
| 4 |
Highbridge Capital Management
New York
|
+$7.86K |
| 5 |
Shaolin Capital Management
Miami,
Florida
|
+$4.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Arbitrage
Greenwich,
Connecticut
|
-$23.2K |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$19.1K |
| 3 |
Heights Capital Management
San Francisco,
California
|
-$10.7K |
| 4 |
Glazer Capital LLC
New York
|
-$10K |
| 5 |
Clear Street
New York
|
-$6.53K |
DMAAR Hedge Fund Activity: Q4 2025 in Review
32 of the 8,306 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q4 2025, worth a combined $3.07M — down 57% from $7.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DMAAR positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 6 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $23.2K. The largest seller was AQR Arbitrage, cutting an estimated $23.2K.
- 32 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $3.07M of Drugs Made In America Acquisition Corp Rights stock for Q4 2025, down 57% quarter-over-quarter.
- 3 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q4 2025 and 2 closed out, a net change of +1 holder.
- The largest Drugs Made In America Acquisition Corp Rights buyer in Q4 2025 was BNP Paribas Financial Markets, an estimated $23.2K added.
- The largest Drugs Made In America Acquisition Corp Rights seller in Q4 2025 was AQR Arbitrage, an estimated $23.2K sold.
Based on aggregated 13F filings for Q4 2025.